Key takeaways:
- Drug industry leaders have expressed their disapproval of the Texas district court judge’s ruling to invalidate the FDA’s approval of the abortion medication mifepristone.
- The leaders have argued that the ruling should be reversed, citing decades of scientific evidence and legal precedent.
- They have called for the ruling to be reversed and for the FDA’s authority to review and approve drugs for use to be respected.
Leaders in the drug industry have expressed their disapproval of a Texas district court judge’s ruling to invalidate the FDA’s approval of the abortion medication mifepristone. In a letter published by The New York Times, the leaders called for the ruling to be reversed, claiming it “ignores decades of scientific evidence and legal precedent.”
The Supreme Court’s reversal of Roe v. Wade last June has brought to federal courts questions of agency protocols and judicial deference, including when and under what situations courts may jettison longstanding scientific evidence. This challenge by anti-abortion physicians and medical groups tests the US Food and Drug Administration’s authority to review and approve drugs for use.
The controversy over medication abortion has the potential for another seismic ruling at the Supreme Court. The leaders in the drug industry have argued that the ruling should be reversed, citing decades of scientific evidence and legal precedent. They have also expressed their concern that the ruling could have a negative impact on women’s constitutional privacy rights and ability to obtain an abortion.
The FDA has yet to respond to the ruling, but the drug industry leaders have made it clear that they are against the decision. They have called for the ruling to be reversed and for the FDA’s authority to review and approve drugs for use to be respected. It remains to be seen how the Supreme Court will rule on this issue, but the drug industry leaders have made their position clear.
Be First to Comment